SCHEMBL6380975

SCHEMBL6380975

CN(C#N)C(=O)[C@H]1CCCC[C@H]1NC(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 5/20 0.61
TAS1R1 Q7RTX1 4/20 0.61
TAS1R2 Q8TE23 4/20 0.61
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
METAP2 P50579 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CTSK P43235 1/20 0.39
P2RX7 Q99572 1/20 0.38
ABCB1 P08183 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6380972 1.00 TAS1R3 (0.61) TAS1R3TAS1R1TAS1R2HPGDSMN1; SMN2
SCHEMBL6386370 0.91 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL6386374 0.91 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL7208807 0.88 TAS1R3 (0.48) TAS1R3TAS1R1TAS1R2ALDH1A1TSHR
SCHEMBL6381420 0.88 TAS1R3 (0.48) TAS1R3TAS1R1TAS1R2ALDH1A1TSHR
SCHEMBL6384210 0.88 TAS1R3 (0.48) TAS1R3TAS1R1TAS1R2ALDH1A1TSHR
SCHEMBL6381110 0.88 HPGD (0.59) TAS1R3TAS1R1TAS1R2HPGDSMN1; SMN2
SCHEMBL6386084 0.83 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2
SCHEMBL6382826 0.83 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2
SCHEMBL6382821 0.83 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US claimed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 US claimed
EP-1294679-B1 BETA-AMINO ACID NITRILE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-09-21 EP disclosed
EP-1294679-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-26 EP disclosed
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US disclosed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 US disclosed
WO-2001096285-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors CTSK, CTSH, UACA TAS1R3 3636/4885TAS1R1 2983/4885TAS1R2 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.